C2PU Stock Analysis: Parkway Life Real Estate | SG
REIT - Healthcare Facilities | SG, Singapore | Market Cap: 2.695m SGD | 12M Return: 7.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.15M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Parkway Life Real Estate Investment Trust (SGX: C2PU) is a Singapore-domiciled healthcare-focused REIT established on 7 July 2007 and listed on the Singapore Exchange on 23 August 2007. The Trust is managed by Parkway Trust Management Limited, with HSBC Institutional Trust Services (Singapore) Limited serving as Trustee, and is included under Singapores Central Provident Fund Investment Scheme.
The Trusts principal activity is investing in income-producing real estate and real estate-related assets across the Asia-Pacific region (including Singapore) used for healthcare and healthcare-related purposes. Eligible assets include hospitals, healthcare facilities, and properties tied to medical research, education, and the manufacture or storage of pharmaceuticals and medical devices, held either directly or through special purpose vehicles.
As a healthcare REIT, Parkway Life operates in a specialized property segment where rental income is typically derived from long-term leases with hospital operators and healthcare tenants, often structured with inflation-linked escalators. Healthcare REITs generally benefit from defensive, recession-resistant demand characteristics due to the non-discretionary nature of medical services.
- Yen weakness pressures Japan hospital rental income
- Rising rates lift refinancing costs on offshore debt
- Aging Asia demographics drive healthcare property acquisitions
| Net Income: 152.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -0.47 > 1.0 |
| NWC/Revenue: -97.41% < 20% (prev 8.41%; Δ -105.8% < -1%) |
| CFO/TA 0.04 > 3% & CFO 111.8m > Net Income 152.8m |
| Net Debt (-45.7m) to EBITDA (111.4m): -0.41 < 3 |
| Current Ratio: 0.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (652.5m) vs 12m ago 7.85% < -2% |
| Gross Margin: 84.28% > 18% (prev 84.00%; Δ 0.29% > 0.5%) |
| Asset Turnover: 5.99% > 50% (prev 5.68%; Δ 0.32% > 0%) |
| Interest Coverage Ratio: 8.38 > 6 (EBIT TTM 111.4m / Interest Expense TTM 13.3m) |
As of July 18, 2026, the stock is trading at SGD 4.16 with a total of 954,700 shares traded. Over the past week, the price has changed by +1.22%, over one month by +5.05%, over three months by +2.97% and over the past year by +7.19%.
Current recommended Stop Loss: 4.00 (which is 3.8% or 3.2 ATR below the current price).
Parkway Life Real Estate has no consensus analysts rating.
P/E Trailing = 17.9565
P/E Forward = 22.8311
P/S = 17.3375
P/B = 1.6059
P/EG = 2.8542
Revenue TTM = 155.9m SGD
EBIT TTM = 111.4m SGD
EBITDA TTM = 111.4m SGD
Long Term Debt = 716.8m SGD (from longTermDebt, last quarter)
Short Term Debt = 166.7m SGD (from shortLongTermDebt, last quarter)
Debt = 2.05m SGD (Leases only: 2.05m)
Net Debt = -45.7m SGD (calculated: Debt 2.05m - CCE 47.8m)
Enterprise Value = 2.65b SGD (2.70b + Debt 2.05m - CCE 47.8m)
Interest Coverage Ratio = 8.38 (Ebit TTM 111.4m / Interest Expense TTM 13.3m)
EV/FCF = 73.34x (Enterprise Value 2.65b / FCF TTM 36.1m)
FCF Yield = 1.36% (FCF TTM 36.1m / Enterprise Value 2.65b)
FCF Margin = 23.17% (FCF TTM 36.1m / Revenue TTM 155.9m)
Net Margin = 97.98% (Net Income TTM 152.8m / Revenue TTM 155.9m)
Gross Margin = 84.28% ((Revenue TTM 155.9m - Cost of Revenue TTM 24.5m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.00 (Enterprise Value 2.65b / Total Assets 2.65b)
Interest Expense / Debt = 647.4% (Interest Expense 13.3m / Debt 2.05m)
Taxrate = 3.50% (5.54m / 158.3m)
NOPAT = 107.5m (EBIT 111.4m * (1 - 3.50%))
Current Ratio = 0.27 (Total Current Assets 57.0m / Total Current Liabilities 208.9m)
Debt / Equity = 0.00 (Debt 2.05m / totalStockholderEquity, last quarter 1.67b)
Debt / EBITDA = -0.41 (Net Debt -45.7m / EBITDA 111.4m)
Debt / FCF = -1.27 (Net Debt -45.7m / FCF TTM 36.1m)
Total Stockholder Equity = 1.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.87% (Net Income 152.8m / Total Assets 2.65b)
RoE = 9.76% (Net Income TTM 152.8m / Total Stockholder Equity 1.56b)
RoCE = 4.88% (EBIT 111.4m / Capital Employed (Equity 1.56b + L.T.Debt 716.8m))
RoIC = 4.41% (NOPAT 107.5m / Invested Capital 2.44b)
WACC = 5.60% (E(2.70b)/V(2.70b) * Re(5.60%) + (debt cost/tax rate unavailable))
Discount Rate = 5.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 73.10% ; FCFF base≈40.4m ; Y1≈35.4m ; Y5≈28.6m
[DCF] Fair Price = 0.77 (EV 458.9m - Net Debt -45.7m = Equity 504.6m / Shares 652.7m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 75.85 | Revenue CAGR: 3.01% | SUE: -0.14 | # QB: 0
EPS current Year (2026-12-31): EPS=0.18 | Chg30d=-0.77% | Revisions=+25% | GrowthEPS=+1.8% | GrowthRev=+6.9%
EPS next Year (2027-12-31): EPS=0.18 | Chg30d=-0.97% | Revisions=-40% | GrowthEPS=+1.8% | GrowthRev=+1.8%
[Analyst] Revisions Ratio: -17% (up=1, down=2)